









Markets
/
Stocks
/
nasdaq-jspr
/

Jasper Therapeutics Inc

JSPR

2.500USD

-0.090-3.47%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

40.55MMarket Cap

LossP/E TTM



Jasper Therapeutics Inc

2.500

-0.090-3.47%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

267 / 506

Overall Ranking

440 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 10 analysts

Buy

Current Rating

15.143

Target Price

+484.67%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS), and stem cell transplant conditioning regimens. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 89.12.

Fairly Valued

The company’s latest PE is -0.41, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 13.30M shares, decreasing 33.79% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 624.60K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.64.

Financial Health

Currency: USD Updated: 2025-09-19

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.43, which is -11.51% below the recent high of -0.38 and -151.11% above the recent low of -1.08.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 267/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 7.40, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Jasper Therapeutics Inc is 20.00, with a high of 25.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

7.40

Change

Support & Resistance

No Data

Analyst Rating

Based on 10 analysts

Buy

Current Rating

15.143

Target Price

+484.67%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Jasper Therapeutics Inc

JSPR

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 4.29, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 2.99 and the support level at 2.26, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.29

Change

-0.12

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.020

Neutral

RSI(14)

40.042

Neutral

STOCH(KDJ)(9,3,3)

42.852

Buy

ATR(14)

0.160

High Vlolatility

CCI(14)

-57.399

Neutral

Williams %R

67.273

Sell

TRIX(12,20)

-0.796

Sell

StochRSI(14)

80.123

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

2.446

Buy

MA10

2.504

Sell

MA20

2.664

Sell

MA50

2.890

Sell

MA100

4.036

Sell

MA200

6.718

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 88.50%, representing a quarter-over-quarter decrease of 1.00%. The largest institutional shareholder is The Vanguard, holding a total of 624.60K shares, representing 3.84% of shares outstanding, with 18.75% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Soleus Capital Management, L.P.

1.49M

Velan Capital Investment Management LP

1.43M

Abingworth Management Limited

1.07M

Qiming U.S. Ventures Management, LLC

928.96K

Kingdon Capital Management, L.L.C.

490.00K

+9.62%

Morgan Stanley & Co. LLC

640.64K

+49.65%

T. Rowe Price Investment Management, Inc.

702.76K

+755.30%

The Vanguard Group, Inc.

Star Investors

679.45K

-4.23%

Integral Health Asset Management, LLC

575.00K

-11.54%

Rock Springs Capital Management LP

545.17K

+17.73%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.96, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 2.82. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.